Small molecule · Inhibitor of SRC proto-oncogene, non-receptor tyrosine kinase (SRC) and YES proto-oncogene 1, Src family tyrosine kinase (YES1) · developed by Nuvectis Pharma
NXP900 is an orally administered inhibitor of SRC family kinases, including SRC and YES1. It binds these kinases and locks them in their closed conformation, inhibiting their kinase activity and their association with signaling partners. It is being studied in EGFR-mutated non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07315113 | Phase 1 | EGFR Mutation Positive Non-small Cell Lung Cancer | Recruiting | NVCT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
EGFR Mutated Non-small Cell Lung Cancer PatientsEGFR Mutation Positive Non-small Cell Lung Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the NVCT page.
See NVCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVCT catalysts and pipeline →